Literature DB >> 6635434

High-pressure liquid chromatographic quantitation of rifampin and its two major metabolites in urine and serum.

A Weber, K E Opheim, A L Smith, K Wong.   

Abstract

Rifampin and two of its major metabolites, 25-O-desacetylrifampin and 3-formylrifamycin SV, were quantitated in serum, urine, and aqueous solutions by high-pressure, reverse-phase liquid chromatography. This rapid, precise, and simple method utilizes a single-step extraction, dual-wavelength monitoring, and quantitation by comparison of the absorbance of the drug or metabolite with that of an internal standard; the wavelengths used are 337 nm and 254 nm. The degrees of precision are +/- 1.3% and + 4.0% for rifampin only (within run and run to run); recovery in the assay is linear, with concentrations of up to 20 micrograms/ml. Comparison of this method with the reference bioassays yielded a good correlation (r = .975). Short turnover time and small sample size make the assay ideal for the monitoring of therapeutic drug concentrations and for pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6635434     DOI: 10.1093/clinids/5.supplement_3.s433

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

1.  Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization.

Authors:  P O'Hara; A J Hickey
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

2.  Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements.

Authors:  M C Nahata; P Fan-Havard; W J Barson; H M Bartkowski; E J Kosnik
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.

Authors:  J Grosset; C Truffot-Pernot; C Lacroix; B Ji
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains.

Authors:  M E Pachón-Ibáñez; F Docobo-Pérez; M E Jiménez-Mejias; J Ibáñez-Martínez; A García-Curiel; C Pichardo; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-19       Impact factor: 3.267

5.  Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.

Authors:  T Q Tan; E O Mason; C N Ou; S L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

6.  Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space.

Authors:  T Mindermann; W Zimmerli; O Gratzl
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

7.  Rifapentine-linezolid-loaded PLGA microspheres for interventional therapy of cavitary pulmonary tuberculosis: preparation and in vitro characterization.

Authors:  Jieyun Huang; Zhi Chen; Ying Li; Li Li; Guangyu Zhang
Journal:  Drug Des Devel Ther       Date:  2017-03-03       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.